
Exciting Breakthrough: China’s Homegrown CTL-4 Inhibitor, IPilimumab Injection by Innovent, Receives Priority Review for Neoadjuvant Colon Cancer Treatment!
Innovent Biologics’ Ipilimumab Injection Receives Priority Review Designation in China for Neoadjuvant Treatment of Colon Cancer On February 23, 2025, Innovent Biologics, Inc., a leading biopharmaceutical company based in both San Francisco, USA, and Suzhou, China, made a significant announcement regarding the acceptance of their New Drug Application (NDA) for ipilimumab injection by the Center…